Thomas J. Whitaker, David M. Routman, Heather Schultz, William S. Harmsen, Kimberly S. Corbin, William W. Wong, and Richard Choo International Journal of Particle Therapy
In the setting of prostate and elective, pelvic nodal radiotherapy for prostate cancer, Intensity Modulated Proton Therapy (IMPT) can significantly reduce the dose to Organs At Risk (OAR) , in comparison to Volumetric-Modulated Arc Therapy (VMAT), and provide adequate target coverage.
The Clinical Target Volumes (CTV) coverage was adequate for both plans with 99% of CTVs receiving ≥ 100% of the prescription doses.
Mean doses to the bladder, rectum, large bowel, and small bowel were lower with IMPT versus VMAT. Mean femoral head dose was greater with IMPT.
The percentage of volumes of rectum receiving ≤ 47.5 Gy, large bowel receiving ≤ 27.5 Gy, small bowel receiving ≤ 30 Gy, and bladder receiving ≤ 37.5 Gy was less with IMPT versus VMAT, largely because of reduction in the low-dose “bath” associated with VMAT.
https://www.theijpt.org/doi/abs/10.14338/IJPT-18-00048.1
